M 2001
Alternative Names: M-2001Latest Information Update: 12 Sep 2023
At a glance
- Originator SyndromeX
- Class Antihyperglycaemics
- Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Metabolic syndrome in Israel (PO) before September 2023
- 12 Sep 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in Israel (PO) before September 2023
- 28 Aug 2020 No recent reports of development identified for preclinical development in Metabolic-syndrome in Israel (PO, Pill)